BAUSCH HEALTH AMERICAS, INC.
🇺🇸United States
Clinical Trials
206
Active:4
Completed:169
Trial Phases
5 Phases
Phase 1:39
Phase 2:43
Phase 3:82
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (195 trials with phase data)• Click on a phase to view related trials
Phase 3
82 (42.1%)Phase 2
43 (22.1%)Phase 1
39 (20.0%)Phase 4
23 (11.8%)Not Applicable
8 (4.1%)Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis
Phase 4
Not yet recruiting
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: Matching placebo rectal foam
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05976802
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
Phase 3
Active, not recruiting
- Conditions
- Hepatic Encephalopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 466
- Registration Number
- NCT05297448
- Locations
- 🇺🇸
Bausch Site 591, Homewood, Alabama, United States
🇺🇸Bausch Site 445, Chandler, Arizona, United States
🇺🇸Bausch Site 453, Sun City, Arizona, United States
Safety, Tolerability, and Pharmacokinetics of Inhaled Virazole Administered Via Air-Jet Nebulizer in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: 50 mg/mL Virazole Inhalant ProductDrug: 100 mg/mL Virazole Inhalant ProductDrug: Placebo
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05229510
- Locations
- 🇨🇦
Bausch Site 1, Mississauga, Ontario, Canada
Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity
Active, not recruiting
- Conditions
- Psoriasis
- Interventions
- Biological: Matched cohort
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 394
- Registration Number
- NCT05132231
- Locations
- 🇨🇦
CARE Site 52, Saint-Charles-Borromée, Quebec, Canada
🇨🇦CARE Site 42, Calgary, Alberta, Canada
🇨🇦CARE Site 26, Calgary, Alberta, Canada
Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease
Phase 2
Completed
- Conditions
- Sickle Cell Disease
- Interventions
- Drug: High Dose Rifaximin ERDrug: Low Dose Rifaximin ERDrug: Low Dose Rifaximin DERDrug: PlaceboDrug: High Dose Rifaximin DER
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT05098028
- Locations
- 🇺🇸
Bausch Site 105, Orange, California, United States
🇺🇸Bausch Site 103, Denver, Colorado, United States
🇺🇸Bausch Site 104, Atlanta, Georgia, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 42
- Next
News
No news found